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ABSTRACT: To better assess biomonitoring data in workers exposed to captan and folpet, 
the kinetics of ring metabolites (tetrahydrophthalimide (THPI), phthalimide (PI) and 
phthalic acid) were determined in urine and plasma of dermally exposed volunteers. A 10 mg 
kg-1 dose of each fungicide was applied on 80 cm2 of the forearm and left without occlusion 
or washing for 24 h. Blood samples were withdrawn at fixed time periods over the 72 h 
following application and complete urine voids were collected over 96 h post-dosing, for 
metabolite analysis. In the hours following treatment, a progressive increase in plasma levels 
of THPI and PI was observed, with peak levels being reached at 24 h for THPI and 10 h for 
PI. The ensuing elimination phase appeared monophasic with a mean elimination half-life 
(t½) of 24.7 and 29.7 h for THPI and PI, respectively. In urine, time courses PI and phthalic 
acid excretion rate rapidly evolved in parallel, and a mean elimination t½ of 28.8 and 29.6 h, 
respectively, was calculated from these curves. THPI was eliminated slightly faster, with a 
mean t½ of 18.7 h. Over the 96-h period post-application, metabolites were almost completely 
excreted, and on average 0.02% of captan dose was recovered in urine as THPI while 1.8% 
of the folpet dose was excreted as phthalic acid and 0.002% as PI, suggesting a low dermal 
absorption fraction for both fungicides. This study showed the potential use of THPI, PI and 
phthalic acid as key biomarkers of exposure to captan and folpet. 
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Table of Contents – Short abstract 
 
To better assess biomonitoring data in workers exposed to captan and folpet, the kinetics of ring 
metabolites were determined in urine and plasma of dermally exposed volunteers. Each fungicide 
was applied on 80 cm2 of the forearm for 24 h. Blood samples and complete urine voids were 
collected respectively over 72 h and 96 h following application. Overall, the studied metabolites 
appeared as key biomarkers of exposure to captan and folpet despite the low dermal absorption 
fraction. 
 
 
 
 
 
 
 
3 
 
INTRODUCTION 
 
The skin is in many instances the primary route of pesticide exposure for agricultural workers, as 
demonstrated by several studies (Ritcey et al., 1987; Fenske, 1990; Woollen, 1993;; Ngo et al., 
2010). It was estimated by a number of authors to account for 90% of exposure whatever the 
activity performed (i.e. preparation of mixture, spraying, material washing, harvesting) (Fenske, 
1990; Vermeulen et al., 2002; Ngo et al., 2010). However, numerous factors influence dermal 
penetration of compounds and affect exposure measurements: physicochemical properties of 
compounds (solubility, chemical structure, partition coefficient), environmental conditions 
(humidity, temperature, wind), vehicle used to apply pesticides (physicochemical properties, 
solubility, pH, concentration), skin properties and cutaneous metabolism (skin condition, skin 
hydratation, type, thickness, enzyme activities, wounds), shunt diffusion, anatomical site of 
exposure (skin thickness, hair follicle size and density), inter-individual variability (age, gender, 
race), dose, duration and occlusion (Lotte et al., 1993;Kromhout and Vermeulen, 2001; Tsai et al., 
2001; Mangelsdorf et al., 2006). Therefore, biological monitoring becomes a reliable means of 
estimating dermal exposure in humans as underlined by several authors (de Cock et al., 1995; Ngo 
et al., 2010; van Welie et al., 1991).. Nonetheless, to be accurate, biomonitoring data need to be 
supported by adequate kinetic studies in human volunteers (Wester and Maibach, 1983; Woollen, 
1993; Ngo et al., 2010). 
 
Captan and folpet are considered as two commonly used fungicides in various crops of many 
countries (Guo et al., 1996; Fenske et al., 1998; Tielemans et al., 1999; Carden et al., 2005; Baldi 
et al., 2006; Juraske et al., 2007; Greenburg et al., 2008). However, only a limited number of 
studies are reported in the literature that use biomonitoring to assess captan exposure in workers 
(Hansen et al., 1978; Mcjilton et al., 1983; Winterlin et al., 1984; Winterlin et al., 1986; Verberk 
et al., 1990; Krieger and Thongsinthusak, 1993; Lavy et al., 1993; de Cock et al., 1995, 1998; 
Krieger and Dinoff, 2000; Hines et al., 2008). Moreover, to our knowledge, no reports are available 
that describe biomonitoring of folpet. As for kinetic studies in human volunteers, one is described 
in the literature following an oral exposure to captan (Krieger and Thongsinthusak, 1993) while 
such data is lacking for folpet. 
 
On the other hand, the metabolism of both fungicides is well documented in in vivo studies in 
animals usually exposed to the radiolabelled compounds and in in vitro studies. According to these 
data, the first step in the metabolism of captan is its breakdown at the N-S link when it is in contact 
with thiol groups (e.g. glutation, cysteine, proteins, etc.), and the reaction is enhanced in alkaline 
medium (Wolfe et al., 1976). From this nonenzymatic process a tetrahydrophtalimide (4,5-
cyclohexene-1,2-dicarboximide; THPI) and a thiocarbonyl chloride are formed, the latter being a 
derivative of the trichloromethylthio group. This thiocarbonyl chloride further reacts with thiols to 
form thiophosgene, a transient metabolite, which readily reacts with cysteine or gluthathione hence 
leading to the formation of thiazolidine-2-thione-4-carboxylic acid (TTCA); two other metabolites 
can also be formed, the dithiobis (or methanesulfonic acid) and its disulphide monoxide derivative, 
arising from the reaction with sulphite ions (DeBaun et al., 1974). From animal studies and two 
occupational studies carried out by Winterlin et al. (1984, 1986) in strawberry pickers and in grape 
field workers, THPI was a suggested as possible biomarker of captan exposure by the 
Environmental Protection Agency (US EPA) (1975). 
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Similar to captan initial metabolism step, folpet is also broken down at the N-S link when it is in 
contact with thiol groups; this leads to the formation of a phthalimide (PI) and a thiocarbonyl 
chloride, but unlike for captan, the reaction is enhanced in acid conditions (Gordon et al., 2001; 
Gordon, 2010). From the thiocarbonyl chloride, the same metabolic reactions as captan occur and 
the same thiol metabolites are formed. On the other hand, the ring metabolite of folpet, PI, is rapidly 
hydrolyzed to phthalamic acid mainly but also to phthalic acid, according to animal studies 
(Gordon et al., 2001; Zainal and Que Hee, 2003; Canal-Raffin et al., 2008; Gordon, 2010). For the 
biological monitoring of exposed individuals, no biomarker was proposed for this fungicide since 
no human study was reported. 
 
Overall, although some metabolism data are available from animal studies for these two fungicides, 
there is a paucity of kinetic data in humans following dermal exposure. These human kinetic data 
are especially needed given the well known interspecies differences in dermal absorption 
(Feldmann and Maibach, 1974; Wester and Maibach, 1983; Kao and Carver, 1990; Fiserova-
Bergerova, 1993; Fenske et al., 1998, Poet and McDougal, 2002). In addition, the dermal route is 
in many circumstances the main route of exposure to pesticides in workers. 
 
The aim to this study was thus to determine the kinetics of captan and folpet ring metabolites in 
accessible biological matrices of dermally exposed volunteers to better assess biomonitoring data 
in workers. It also aimed to compare the toxicokinetics of captan and folpet metabolites, given the 
related chemical structure of the parent compound and initial breakdown metabolites. 
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MATERIALS AND METHODS 
 
 
Study design 
 
The study design was similar to the one previously described for volunteers orally exposed to the 
same fungicides and reported in Berthet et al. (2011a). Thus, a controlled kinetic time course study 
in accessible biological matrices of healthy subjects was conducted following a dermal exposure 
to captan and folpet. Captan and folpet metabolites were measured in urine and blood samples 
collected prior to treatment to obtain pre-test values, and then at predetermined time points post-
dosing (amounting to a total of 9 samples for plasma and 11 samples for urine). 
 
The experimental protocol and consent forms were approved by the Permanent Ethics Committee 
for Clinical Research of the Faculty of Biology and Medicine of the University of Lausanne and 
the Research Ethics Committee of the Faculty of Medicine of the University of Montreal. All the 
participants gave their written consent, and were informed of the risks of participating and their 
right to withdraw from the study at anytime. As suggested by the Ethics Committee who considered 
the study as very restrictive, the participants received a monetary compensation for their time and 
any inconvenience caused. 
 
Subjects studied 
 
Participants were recruited on a voluntary basis among the medical students of the University of 
Lausanne, Switzerland. The volunteers were nine male students aged from 20 to 30 years old, 
weighing 60 to 85 kg and measuring 169 to 184 cm. They were healthy, non-smokers and did not 
take medication or drugs. They underwent a medical examination by an occupational physician 
prior to enrolment. They had never been exposed to captan or folpet, except an acute oral dose of 
1 mg kg-1 two weeks before, and perhaps through their diet. During the study period and the two-
days prior to dosing, they were asked not to eat fruits and vegetables in order to limit ingestion of 
contaminated food. They were also requested to avoid consumption of alcohol during this period, 
since it is known to affect the metabolism of some chemical compounds. 
 
Dosing and sampling 
 
The experimental dosing and sampling was also conducted at the Institute for Work and Health of 
Lausanne, Switzerland. The morning of study onset, each participant was asked to collect his 
complete first morning urine void, to obtain pre-test values; they then spent the first day of the 
study in a room at the Institute for dosing and the first 12-h sampling. On the following 3-day 
sampling period, participants visited the Institute for their daily morning blood sampling and 
handing-in urine collections. 
 
A dose of captan or folpet equivalent to 10 mg kg-1 body wt was applied on 80 cm2 of one of the 
forearm of each volunteer (n = 5 for captan and n = 4 for folpet). Fungicides used to prepare the 
exposure dose of volunteers were Captan PESTANAL® (assay (HPLC) area 99.1 to 99.4%) and 
Folpet PESTANAL® (assay (HPLC) area 99.5 to 99.9%). Both were purchased from Fluka – 
Sigma-Aldrich (Buchs, St Gallen, Switzerland). The single dose was weighted in a labelled glass 
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container and adjusted to the weight of each volunteer. The fungicide dose was dissolved in 30 mL 
of acetone, mixed and applied on the skin. To ensure that the dose was applied on 80 cm2, a 20 x 4 
cm cardboard frame was fixed on the forearm of each volunteer to delimit the area. To avoid 
injuring the participant, a plastic pipette was used to apply the dose. The participants washed their 
arm only 24 h following application. The exposed area was not occluded to avoid influencing 
absorption (Feldmann and Maibach, 1974; Wester and Maibach, 1983; Curdy et al., 2004; Carden 
et al., 2005), except some of the participants wore long sleeve shirts since the study was performed 
during the winter season. 
 
Complete micturitions were then collected at pre-determined times over the 96–h period post-
dosing, that is at around 0, 3, 6, 9, 12, 24, 36, 48, 60, 72, 84 and 96 h post-dosing. Each timed-void 
was collected in separate polypropylene Nalgene® bottles of 1 l. To assist participants, they 
received a schedule specifying the date and the required time of urine collection. They then only 
had to complete the sheet with the actual time of collection and to indicate whether or not there 
were any urine losses. They also had to identify their plastic bottles with distinct pre-printed labels 
indicating the code, and mark the date and time of urine collection. 
 
Once collected, urine samples were kept in the refrigerator prior to measurement of total urine 
volume per void. To allow repeated analysis while avoiding possible degradation due to freezing 
and defreezing of samples, each urine collection then was aliquoted in 4 labelled tubes of 15 ml 
and one bottle of 120 ml before storage at -20°C until analysis of captan or folpet metabolites. 
 
Blood samples of 15 ml were also collected at specific times, that is at t = 0, 2, 4, 6, 8, 10, 24, 48 
and 72 h post-dosing. To facilitate collection, a catheter was installed by a nurse prior to dosing 
along with a drip system of physiological saline the first day of sampling. Blood was withdrawn 
by the nurse into vacutainers pre-labelled with a code, the date and time of sampling. Immediately 
after collection, blood samples were centrifuged to precipitate red blood cells and isolate plasma. 
The plasma samples were then split into 3 labelled aliquots and stored at -20°C until analysis of 
captan and folpet metabolites. 
 
During the study period, volunteers were also asked to fill a questionnaire to document personal 
information (weight, height), life habits (i.e. physical activities, smoking), medication intake 
(including ibuprofen), alcohol consumption during the 3 days prior to treatment, consumption of 
fruits, vegetables and cereals during the 4 days prior to treatment and possible dosing-related 
symptoms. 
 
Chemicals and reagents 
 
Reference standards (>99% purity) were obtained from Sigma-Aldrich (Buchs, St Gallen, 
Switzerland), except for deuterated cis-1,2,3,6-tetrahydrophthalimide (THPI-d) (99% purity), 
which was purchased from Cambridge Isotope Laboratories Inc. (Andover, MA, USA). HPLC 
grade acetonitrile, methanol, ethyl acetate and dichloromethane were also obtained from Sigma-
Aldrich (Buchs, St Gallen, Switzerland), along with N,O-bis(trimethylsilyl)trifluoroacetamide 
(BSTFA), the reagent used to derivatize the phthalic acid molecule. HCl and ammonium sulphate 
were purchased from Merck (Zug, Switzerland). Water was purified using a TKA GenPure water 
treatment system obtained from TKA Wasseraufbereitungssysteme GmbH (Niederelbert, 
Germany).  
7 
 
 
Analysis of THPI and PI in plasma and urine 
 
A liquid chromatography - atmospheric pressure chemical ionization-tandem mass spectrometry 
(LC/APCI-MS/MS) method was developed to analyze THPI and PI in urine and plasma, and is 
described elsewhere (Berthet et al., 2011b). Briefly, THPI and PI were isolated by solid phase 
extraction (SPE) (in the case of plasma, following a denaturation of proteins), eluted in 
dichloromethane and analyzed using a Varian Model 212-LC Binary Gradient LC system (Les 
Ulis, France) connected to a Prostar model 410 autosampler (Varian, Les Ulis, France) and coupled 
to a Model 1200 L quadrupole MS (Varian, Les Ulis, France) operating in APCI mode. The APCI 
interface was operated in negative ion mode. The compounds were separated using a C18 Zorbax 
Eclipse Plus column (4.6 x 150 mm, 3.5 µm) from Agilent (Morges, Switzerland). The mobile 
phase consisted of: eluent A composed of 90% water and 10% acetonitrile (9:1), and eluent B of 
10% water – 90% acetonitrile (1:9). For THPI analysis, 10 µl of the sample were injected and 
elution was performed in 26 min using a solvent gradient at a flow rate of 0.8 ml min-1, and for PI 
analysis, 10 µl of the sample were also injected and elution was performed in 33 min in isocratic 
mode at a flow rate of 0.8 ml min-1. The fragments analyzed were m/z 149.4/95.6 for THPI with a 
collision energy (CE) of 19.5 V, m/z 156.1/95.6 for the internal standard THPI-d (CE of 22.5 V) 
and m/z 145.8 for PI (no fragmentation). The analytical limit of detection for THPI was 3.82 nmol 
l-1 of urine and 9.76 nmol l-1 of plasma and, for PI, 7.72 nmol l-1 of urine and 14.8 nmol l-1 of 
plasma. The quantification of THPI or PI was obtained from standard calibration curves prepared 
in urine or plasma adjusted by the THPI-d internal standard surface area. 
 
Analysis of phthalic acid in urine 
 
A gas chromatography mass spectrometry (GC-MS) method was developed for the analysis of 
phthalic acid in urine, as previously described (Berthet et al., 2011c). In short, urine samples were 
subjected to an acid hydrolysis prior to liquid-liquid extraction with ethyl acetate and derivatization 
with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA). Analysis was then performed using an 
Agilent Mass Selective Detector (MSD) G1098A (Agilent Technologies Inc, Waldbronn, 
Germany) coupled with a HP 5973 mass spectrometer (Agilent Technologies Inc, Waldbronn, 
Germany). Separation of the analytes was performed using a 60 m CP-SIL 8 CB column (1 µm 
film thickness, 250 µm I.D.) (Varian, Les Ulis, France). The initial column temperature was 200°C 
for 3 min, then it was increased to 260°C at 30°C min-1, held for 11 min, and finally increased to 
280°C at 35°C min-1 and held for 4 min. For the analysis, 2 µl were injected using a 5 ml min-1 
split. The ions monitored were trimethylsilyl phthalic acid (TMS phthalic acid) with m/z 295 and 
and the internal standard TMS methylhippuric acid with m/z 220. The quantification was obtained 
from standard calibration curves of phthalic acid prepared in urine and adjusted by the 
methylhippuric acid internal standard surface area. The analytical limit of detection was 0.6 µmol 
l-1 urine. 
 
Calculations 
 
The molar fraction of captan or folpet administrated dose recovered in urine as THPI, PI or phthalic 
acid was calculated from the following equation: 
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where Qurinary metabolite corresponds to total amounts of THPI, PI or phthalic acid in urine over the 
96-h urine collection period (mg), MWparent compound is the molecular weight of captan or folpet, 
MWmetabolite is the molecular weight of THPI, PI or phthalic acid and Doseparent compound is the orally 
administered dose of captan or folpet (mg). 
 
Toxicokinetic analysis 
 
To determine elimination rate constants of THPI and PI in plasma and in urine, we considered that, 
following peak levels, elimination was monophasic and a first-order reaction. The elimination rate 
constant (k) was thus calculated from the slope of the linear terminal phase of the plasma or urine 
time profile. The apparent elimination half-life (t1/2) was then defined using the equation t1/2 = 0.693 
k-1 (Hayes, 2008). 
 
From plasma concentration (C) - time profile, we also calculated the area under the concentration-
time curve (AUC), the area under the first moment of concentration-time curve (AUMC), the mean 
residence time (MRT), the plasma clearance (CL) and the apparent volume of distribution (Vd). 
Equations used to calculate these parameters are: 
𝐴𝐴𝐴𝐴𝐴𝐴 = 12�(𝑡𝑡𝑢𝑢
∀𝑢𝑢
− 𝑡𝑡𝑢𝑢+1)[𝐴𝐴(𝑡𝑡𝑢𝑢) + 𝐴𝐴(𝑡𝑡𝑢𝑢+1)] 
𝐴𝐴𝐴𝐴𝑀𝑀𝐴𝐴 = 12�(𝑡𝑡𝑢𝑢
∀𝑢𝑢
− 𝑡𝑡𝑢𝑢+1)[𝑡𝑡𝑢𝑢𝐴𝐴(𝑡𝑡𝑢𝑢) + 𝑡𝑡𝑢𝑢+1𝐴𝐴(𝑡𝑡𝑢𝑢+1)] 
𝑀𝑀𝑀𝑀𝑀𝑀 =  𝐴𝐴𝐴𝐴𝑀𝑀𝐴𝐴
𝐴𝐴𝐴𝐴𝐴𝐴
 
𝐴𝐴𝐶𝐶 =  𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐷𝐷𝐴𝐴 𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷
𝐴𝐴𝐴𝐴𝐴𝐴   
𝑉𝑉𝐴𝐴 =  𝐶𝐶𝐶𝐶
𝑘𝑘
   where k is the overall elimination rate from blood 
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RESULTS 
 
 
Time courses of THPI and PI in plasma 
 
The time courses of THPI and PI in plasma of volunteers over the 72-h period following an 
application of captan or folpet (10 mg kg-1 body wt) are presented in Fig. 1. In control samples 
taken prior to captan or folpet ingestion (t0), concentrations of THPI were below the analytical limit 
of detection and those of PI were very low, in the order of 3.9 nmol l-1. Following application, a 
progressive increase in plasma levels of THPI and PI was observed, with peak levels being reached 
24 h post dosing for THPI and 10 h post-treatement for PI. Subsequent elimination phase of THPI 
and PI from plasma over the 24- to 72-h period post-dosing appeared monophasic with an apparent 
elimination half-life of 24.7 and 29.7 h, respectively (Table 1). From the THPI and PI time profiles 
in plasma, various toxicokinetic parameters were calculated and are presented in Table 2. These 
show that following dermal application, THPI had a greater bioavailability and slightly faster 
clearance rate than PI; on the other hand, they had similar, relatively small, volume of distribution 
(Vd).  
 
Time courses of THPI, PI and phthalic acid in urine 
 
Figure 2 presents the time courses of THPI, PI and phthalic acid excretion rate in the urine of 
volunteers over a 96-h period following application of 10 mg kg-1 body wt of captan or folpet. As 
expected, these profiles evolved in unison with the blood profiles (see Figure 1 for comparison). It 
is readily observed from Fig. 2 that, following peak excretion, elimination rate time courses of PI 
and phthalic acid were parallel, with mean apparent elimination half-lives of 28.8 and 29.6 h, 
respectively, calculated for the 36- to 96-h period post-dosing (Table 1). THPI elimination was 
slightly faster with an apparent elimination half-life of 18.7 h calculated for the same period (Table 
1). 
 
Figure 3 displays the corresponding cumulative urinary excretion time courses of the three 
metabolites over the 96-h collection period post-dosing. From these data, it was calculated that 
1.8% of the applied dose of folpet was recovered in urine as phthalic acid as compared to only 
0.002% for PI. This indicates that phthalic acid was present in urine in 1 000-fold higher amounts 
than PI despite the fact that they had similar urinary time-profiles and thus elimination half-lives. 
By comparison, the percentage of applied captan dose recovered in urine as THPI was 0.02%, 
which is 10-fold higher than the percentage of applied folpet dose found as PI in urine. 
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DISCUSSION 
 
Kinetics of biomarkers of exposure to captan and folpet in dermally exposed volunteers 
 
The present study provided novel data on the toxicokinetics of key biomarkers of exposure to 
captan and folpet following dermal exposure in humans. Such dermal kinetic data were lacking for 
both fungicides, not only in humans but also in animals. The studied biomarkers were found to be 
rapidly formed and eliminated from the body, with elimination half-lives following dermal 
application in the order of 20-25 h for THPI and 30 h for folpet ring-metabolites. No built up in the 
body was apparent; elimination from the body was complete 96 h post-treatment. The small 
percentage of dose recovered in urine as the studied biomarkers also suggests a low dermal 
absorption fraction of both captan and folpet. 
 
Although dermal kinetic data on these specific biomarkers were not available in the literature for 
comparison purpose, the dermal absorption, tissue distribution and excretion of total radioactivity 
has been documented in animals dermally exposed to labelled captan or folpet (Grissom et al., 
1985; Shah et al., 1987; Fisher et al., 1992). These animal data are in accordance with current 
results, showing a rapid elimination of labelled dose following dermal exposure and a low dermal 
absorption fraction. In particular, in one of the few published dermal kinetic studies of captan in 
animals, Fisher et al. (1992) observed that, on average, 82% of a dermally applied dose of 14C-
ring-captan (286 nmol cm-2) were recovered in the analyzed tissues and fluids (kidneys, liver, total 
skin, carcass, urine, feces and blood) of aging Fischer 344 female rats (33 and 82 days) over the 0-
120 h collection period. After 120 h, on average, 10.8 and 11.5% of the applied dose had penetrated 
young and adult skin, respectively, and 9% of dose in young rats and 10% of dose in adults were 
recovered as total radiactivity in urine. Similar to published oral experiments in rats exposed to 
ring-labelled captan, this implied that most of the absorbed dose was excreted in urine while very 
little was excreted in feces.  
 
Similarly, in one of the only dermal penetration study on folpet in animals, Shah et al. (1987) 
estimated a low dermal absorption fraction, as assessed from analysis of radioactivity in skin and 
carcasses at 72 h post-application of a low, medium and high dose of 14C-trichloromethyl labelled 
folpet in Fisher 344 rats as well as in urine and feces collected over the 72-h period post-dosing. 
On average 12% of the low dose of folpet were calculated to be absorbed through the skin during 
that time (application of 0.1 µmol cm-2 on 2.8 and 5.6 cm2 of young and adult rats, respectively) as 
compared to only 3 and 1 % for the two higher doses (application of 0.5 and 2.7 µmol cm-2, 
respectively). 
 
The study of Krieger and Thongsinthusak (1993) is the only available published time course study 
of specific THPI biomarker in the urine of volunteers exposed under controlled conditions. In the 
latter study, two volunteers were orally exposed to 0.1 and 1 mg kg-1 captan and it was observed 
that THPI represented 1 to 3% of the administered dose. In a preliminary attempt, captan was also 
applied to the hands, forearms and inguinal region of the volunteers (15 mg on 40 µg cm-2 region 
of the skin of volunteers weighing 150 and 84 kg) but the dose was too low to allow quantification 
of THPI in urine. Nonetheless, they estimated a captan dermal absorption of 0.3% per day for 
humans. 
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Furthermore, from the observed kinetic data in the current study, some essential biological 
determinants can be identified. In particular, the dermal kinetics of the two studied biomarkers of 
exposure to folpet, PI and phthalic acid, exhibited similar time profiles, indicating that they were 
governed by the same essential biological processes. However, phthalic acid was found to be 
present in much higher amounts than PI in urine, in line with the substantial metabolism of PI into 
acids documented by some authors following oral or intraperitoneal exposure (Ackermann et al., 
1978; Chasseaud et al., 1991; Canal-Raffin et al., 2008; Gordon, 2010). In particular, Canal-Raffin 
et al. (2008) reported an elimination half-life of on average 2.5 h for PI in plasma following a single 
intraperitoneal folpet dose of 10 mg kg-1 in Wistar rats. Ackermann et al. (1978) also estimated a 
PI half-life of 2 h in rat fetuses following an oral administration of 2.5 mg kg-1 of 15N-phthalimide 
to pregnant Wistar-strain albino rats and observed a fast metabolism of PI into phthalamic acid. 
This latter metabolite is then transformed to phthalic acid, the final ring-metabolite of folpet 
(Williams and Blanchfield, 1974). 
 
By comparison, current results suggest that THPI is a minor metabolite of captan, since urinary 
amounts were found to represent only a very small percentage (0.02%) of the dermal dose in 
volunteers. This is corroborated by oral mass-balance data in animals following radiolabelled 
doses, with specific identification of metabolites in urine, showing in particular the presence of 3-
hydroxy-4,5-cyclohexene-1,2-dicarboximide (3-OH-THPI) derivative as a more important 
metabolite (Lappin and Havell, 1990; Gordon, 2010). 
 
Comparison of the kinetics of captan and folpet ring metabolites in dermally exposed 
volunteers  
 
This study also allowed comparing the kinetics of captan and folpet ring metabolites in dermally 
exposed volunteers. Although these biomarkers are rapidly eliminated from the body following 
dermal exposure with apparent negligible tissue accumulation, differences in the dermal kinetics 
of THPI ring-metabolite of captan as compared to that of PI and phthalic acid ring-metabolites of 
folpet were observed. THPI was eliminated slightly faster than folpet ring-metabolites. Dermal 
absorption fraction also appeared more important for folpet than captan when comparing amounts 
of metabolites recovered overall in urine (1.8% of dermal folpet dose recovered as phthalic acid in 
urine as compared to 0.02% of dermal captan dose found as THPI in urine with reference to 25 and 
3.5% respectively after oral administration). 
 
Comparison of the dermal and oral kinetics of ring-metabolites of captan and folpet 
 
When compared to oral kinetics, the dermal kinetics of captan and folpet ring-metabolites in 
humans exhibited marked differences. Indeed, the plasma time profile of THPI observed in the 
current study following dermal application in volunteers together with calculated toxicokinetic 
parameters can be compared to the ones described in Berthet et al. (2011a) following an oral 
administration in the same volunteers. The apparent elimination half-life of THPI calculated from 
the terminal elimination phase along with the plasma clearance indicate a somewhat slower 
elimination of THPI from plasma following dermal application than after ingestion (average t½ of 
24.7 and 15.7 h, respectively; mean CL of 0.24 and 0.18 l h-1, respectively). THPI was also found 
to have a 10-fold lower area under the curve following dermal application than oral exposure 
(average AUC of 137.3 and 1650 (nmol x h l-1) kg-1), respectively. As compared to ingestion, 
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dermal exposure is thus associated with a lower absorption fraction and slower absorption rate, the 
latter influencing the elimination rate of THPI from plasma. 
 
Similarly, the current time courses of PI in plasma of volunteers and associated toxicokinetic 
parameters can also be compared to the oral time courses in the same volunteers described in 
Berthet et al. (2011a). The apparent elimination half-life and plasma clearance rate of PI were 
similar for both routes of exposure, showing a negligible effect of the dermal absorption rate on 
elimination rate of PI from plasma (average t½ of 29.7 and 31.5 h, respectively; mean CL of 0.13 
and 0.09 l h-1, respectively). On the other hand, PI was found to have a slightly higher area under 
the curve following dermal application than oral exposure (average AUC of 26.1 and 13.4 (nmol 
x h l-1) kg-1), respectively; this is compatible with a proportionally more extensive site-of-entry 
metabolism of PI into its derivatives following oral administration. 
 
The urinary time course of THPI observed in this study following dermal application in volunteers 
can further be compared to the one reported in Berthet et al. (2011a) following an oral 
administration, again in the same volunteers. In accordance with the plasma profiles, the apparent 
elimination half-life of THPI calculated from urinary excretion rate time courses indicates a slightly 
slower elimination of THPI following dermal application than ingestion (average t½ of 18.7 and 
11.7 h, respectively). The percentage of captan dose recovered in urine as THPI was also 175 times 
lower following dermal exposure than after oral administration (on average 0.02 versus 3.5%), 
indicating a very low dermal absorption fraction. 
 
Similarly, the dermal time courses of folpet metabolites in urine can be compared to the ones 
reported in Berthet et al. (2011a) following oral exposure in the same volunteers. In accordance 
with the plasma profiles, the apparent elimination half-lives of PI and phthalic acid were similar 
for both routes of exposure, showing a negligible effect of the dermal absorption rate on elimination 
rate of PI and phthalic acid (average t½ of 28.8 and 27.3 h, respectively for PI, and 29.6 and 27.6 h 
for phthalic acid, respectively). On the other hand, the percentage of folpet dose recovered in urine 
as PI and phthalic acid was 10- and 14-fold lower, respectively, following dermal exposure than 
after oral administration (on average 0.002 versus 0.02% for PI and 1.8 versus 25% for phthalic 
acid), indicating a low dermal absorption fraction. 
 
Animal studies also confirm a lower absorption fraction of captan and folpet following dermal 
exposure as compared to an oral exposure. Indeed, as mentioned previously, Fisher et al. (1992) 
estimated a dermal absorption fraction of on average 10.8 to 11.5% in Fisher rats based on the time 
course in skin and excreta over a 120-h period following a dermal dose of 286 nmol cm-2. As for 
Grissom et al. (1985), they estimated a dermal penetration of 7.8% in Dublin ICR mice dermally 
exposed to 1 mg kg-1 cm-2 of 14C-captan, as assessed from analysis of radioactivity in skin, tissues 
and excreta (urine, feces and exhaled air) over a 24-h period post-dosing. Moreover, again as 
mentioned previously, on average 12, 3 and 1% of folpet were absorbed through the skin over a 
72-h period following a dermal application of 0.1, 0.5 and 2.7 µmol cm-2 of radiolabelled folpet in 
Fisher rats, respectively (Shah et al., 1987). By comparison, following oral exposure, Trivedi 
(1990) observed that about 75% of a 10 mg kg-1 dose of 14C-ring labelled captan in male Sprague-
Dawley rats were recovered in urine as 14C-equivalents over the 24-h period post-dosing as 
compared to 6.5% in feces. Similarly, following an oral administration of 10 mg kg-1 of 14C-labelled 
folpet in rats, Chasseaud et al. (1991) also showed that 92% of the dose were recovered in urine as 
14C equivalents as compared to 6% in feces. 
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Potential use of ring-metabolites of captan and folpet as biomarkers of exposure in workers 
on the basis of the current dermal kinetic data 
 
The current dermal kinetic data in volunteers can serve to establish the potential use of ring-
metabolites of captan and folpet as biomarkers of exposure in workers. Although THPI and PI in 
urine represented only a small fraction of the applied dose, their kinetics could easily be established 
in exposed volunteers. Given these data and the fact that THPI and PI are metabolites specific to 
captan and folpet, respectively, as well as the availability of simple and sensitive analytical methods 
for their detection, their use as bioindicators of exposure to captan and folpet should be further 
considered in worker biomonitoring studies. The measured phthalic acid is less specific since it is 
also a phthalate metabolite (Blount et al., 2000; Vermeulen et al., 2001; Kato et al., 2005; Lim et 
al., 2007, Silva et al., 2007). However,it is a major biomarker of folpet and its measurement could 
usefully serve in combination with that of PI to assess worker exposure. 
 
It should be mentioned that the ring-metabolites are to be used as bioindicators of exposure and 
thus to reflect absorbed doses of captan or folpet. These biomarkers are not implicated in the 
pathways leading to toxicity. Eventual assessment of metabolites derived from the thiophosgene 
moiety (DeBaun et al.,1974) may help link biomarkers of exposure to potential health outcomes. 
 
As compared to current results, some differences in the dermal absorption fraction and rate may be 
observed in the context of a dermal exposure in workers, given the use of acetone as a vehicle for 
dose administration in this study, which enhances permeability of the skin and thus absorption 
(Tsai et al., 2001). Some differences in the absorption could also occur in workers depending on 
the anatomical site exposed (Feldmann and Maibach, 1974). However, the forearm was selected in 
the present study as the application site, since hands and arms are the anatomical regions most 
exposed in workers (Mcjilton et al., 1983; Zweig et al., 1985; de Cock et al., 1998; Hughes et al., 
2006; Ngo et al., 2010). 
 
Overall, the present study provided new data of the dermal kinetics of key biomarkers of exposure 
to captan and folpet. It highlighted distinctions in the kinetics of captan and folpet phthalimide 
derivatives, but also route-to-route differences. However, THPI and PI appeared as convenient 
biomarkers to quantify captan or folpet exposure. As for phthalic acid, even if it is not a metabolite 
specific to folpet, it is a derivative of PI that can be used to corroborate results obtained for PI. 
 
 
14 
 
Acknowledgements 
 
Authors wish to thank Dr. Michèle Berode and the technicians P. Stefan, M. Nobel and C. Kohler 
(Institute for Work and Health) for their help in organizing the study. We also thank Dr. Khanh 
Huynh (Institute for Work and Health) for his help with the LC/MS/APCI system. The study was 
funded by the ANSES (Agence Nationale de Sécurité Sanitaire de l’alimentation, de 
l’environnement et du Travail) and Aurélie Berthet received a Ph.D. scholarship from the Institut 
de recherche Robert-Sauvé en santé et sécurité du travail du Québec for this research. 
15 
 
REFERENCES 
 
 
Ackermann H, Faust H, Kagan YS, Voronina VH. 1978. Metabolic and Toxic Behaviors of 
Phthalimide Derivatives in Albino-Rat .2. Placental Passage of Chloromethyl Phthalimide, 
Oxymethyl Phthalimide, and Phthalimide - Their Fetal Metabolism. Arch. Toxicol. 40: 255-261. 
 
Baldi I, Lebailly P, Jean S, Rougetet L, Dulaurent S, Marquet P. 2006. Pesticide contamination of 
workers in vineyards in France. J. Expo. Sci. Environ. Epidemiol. 16: 115-124. DOI: 
10.1038/sj.jea.7500443. 
 
Berthet A, Bouchard M, Vernez D. 2011a. Toxicokinetics of captan and folpet biomarkers in orally 
exposed volunteers. In press. DOI: 10.1002/jat.1653. 
 
Berthet A, Bouchard M, Schüpfer P, Vernez D, Danuser B, Huynh C K. 2011b. A liquid 
chromatography - tandem mass spectrometry (LC/APCI-MS/MS) method for the quantification of 
captan and folpet phthalimide metabolites in human plasma and urine. Anal. Bioanal. Chem. 339: 
2243-2255. DOI: 10.1007/s00216-010-4601-z. 
 
Berthet A, Berode M, Bouchard M. 2011c. Development and validation of a chemical hydrolysis 
method and GC-MS determination for phtalamic and phtalic acids in urine samples. Application to 
the assessment of Folpet exposure. In press. 
 
Blount BC, Milgram KE, Silva MJ, Malek NA, Reidy JA, Needham LL, Brock JW. 2000. 
Quantitative detection of eight phthalate metabolites in human urine using HPLC-APCI-MS/MS. 
Anal. Chem. 72: 4127-4134. 
 
Canal-Raffin M, Receveur M, Martinez B, Titier K, Ohayon C, Baldi I, Molimard M, Moore N, 
Brochard P. 2008. Quantification methods of folpet degradation products in plasma with HPLC-
UV/DAD: Application to an in vivo toxicokinetic study in rats. J. Chromatogr. B-Anal. Technol. 
Biomed. Life Sci. 865: 106-113. DOI: 10.1016/j.jchromb.2008.02.011. 
 
Carden A, Yost MG, Fenske RA. 2005. Noninvasive method for the assessment of dermal uptake 
of pesticides using attenuated total reflectance infrared spectroscopy. Appl. Spectrosc. 59: 293-
299. 
 
Chasseaud L, Wood S G, Cheng K, Hall M, Fitzpatrick K, Iqbal S, Barlett A. Metabolic fate of 
14C-folpet in Sprague-Dawley rats. Huntingdon Research Centre Ltd.: Huntingdon. Unpublished 
Report No HRC/ MBS 41-91499. 
 
Curdy C, Naik A, Kalia YN, Alberti I, Guy RH. 2004. Non-invasive assessment of the effect of 
formulation excipients on stratum corneum barrier function in vivo. Int. J. Pharm. 271: 251-256. 
 
de Cock J, Heederik D, Kromhout H, Boleij JS M, Hoek F, Wegh H, Ny ET. 1998. Exposure to 
captan in fruit growing. Am. Ind. Hyg. Assoc. J. 59: 158-165. 
 
16 
 
de Cock J, Heederik D, Hoek F, Boleij J, Kromhout H. 1995. Urinary excretion of 
tetrahydrophtalimide in fruit growers with dermal exposure to captan. Am. J. Ind. Med. 28: 245-
256. 
 
DeBaun JR, Miaullis JB, Knarr J, Mihailovski A, Menn JJ. 1974. The fate of N-
trichloro(14C)methylthio-4-cyclohexene-1,2-dicarboximide((14C)captan) in the rat. Xenobiotica 
4: 101-119. DOI: 10.3109/00498257409049350. 
 
Feldmann RJ, Maibach HI. 1974. Percutaneous penetration of some pesticides and herbicides in 
man. Toxicol. Appl. Pharmacol. 28: 126-132. 
 
Fenske RA. 1990. Nonuniform dermal deposition patterns during occupational exposure to 
pesticides. Arch. Environ. Contam. Toxicol. 19: 332-337. 
 
Fenske RA, Schulter C, Lu C, Allen EH. 1998. Incomplete removal of the pesticide captan from 
skin by standard handwash exposure assessment procedures. Bull. Environ. Contam. Toxicol. 61: 
194-201. 
 
Fiserova-Bergerova V. 1993. Relevance of occupational skin exposure. Ann. Occup. Hyg. 37: 673-
685. 
 
Fisher HL, Hall LL, Sumler MR, Shah PV. 1992. Dermal penetration of [14C]captan in young and 
adult rats. J. Toxicol. Environ. Health. 36: 251-271. 
 
Gordon EB. 2010. Captan and folpet. In Handbook of pesticide toxicology, Krieger RI (ed). 
Elsevier: New York; 1915-1949. 
 
Gordon EB, Ehrlich T, Mobley S, Williams M. 2001. Measurement of the reaction between the 
fungicides captan or folpet and blood thiols. Toxicol. Meth. 11: 209-223. 
 
Greenburg DL, Rusiecki J, Koutros S, Dosemeci M, Patel R, Hines CJ, Hoppin JA, Alavanja MC. 
2008. Cancer incidence among pesticide applicators exposed to captan in the Agricultural Health 
Study. Cancer Causes Control 19: 1401-1407. DOI: 10.1007/s10552-008-9187-9. 
 
Grissom RE, Brownie C, Guthrie FE. 1985. Dermal Absorption of Pesticides in Mice. Pest. 
Biochem. Physiol. 24: 119-123. 
 
Guo YLL, Wang BJ, Lee CC, Wang JD. 1996. Prevalence of dermatoses and skin sensitisation 
associated with use of pesticides in fruit farmers of southern Taiwan. Occup. Environ. Med. 53: 
427-431. 
 
Hansen JD, Schneider BA, Olive BM, Bates JJ. 1978. Personnel safety and foliage residue in an 
orchard spray program using azinphosmethyl and captan. Arch. Environ. Contam. Toxicol. 7: 63-
71. 
 
Hayes AW. 2008. Toxicokinetics. In Principles and Methods of Toxicology, 5th edition, Hayes AW 
(ed). Taylor and Francis Group: Boca Raton; 179-230. 
17 
 
 
Hines CJ, Deddens JA, Jaycox LB, Andrews RN, Striley CAF, Alavanja MCR. 2008. Captan 
exposure and evaluation of a pesticide exposure algorithm among orchard pesticide applicators in 
the agricultural health study. Ann. Occup. Hyg. 52: 153-166. 
 
Hughes EA, Zalts A, Ojeda JJ, Flores AP, Glass RC, Montserrat JM. 2006. Analytical method for 
assessing potential dermal exposure to captan, using whole body dosimetry, in small vegetable 
production units in Argentina. Pest. Manag. Sci. 62: 811-818. DOI: 10.1002/ps.1232. 
 
Juraske R, Anton A, Castells F, Huijbregts MA. 2007. Human intake fractions of pesticides via 
greenhouse tomato consumption: comparing model estimates with measurements for Captan. 
Chemosphere 67: 1102-1107. 
 
Kao J, Carver MP. 1990. Cutaneous Metabolism of Xenobiotics. Drug Metab. Rev. 22: 363-410. 
 
Kato K, Silva MJ, Needham LL, Calafat AM. 2005. Determination of 16 phthalate metabolites in 
urine using automated sample preparation and on-line preconcentration/high-performance liquid 
chromatography/tandem mass spectrometry. Anal. Chem. 77: 2985-2991. 
 
Krieger RI, Dinoff TM. 2000. Captan fungicide exposures of strawberry harvesters using THPI as 
a urinary biomarker. Arch. Environ. Contam. Toxicol. 38: 398-403. 
 
Krieger RI, Thongsinthusak T. 1993. Captan Metabolism in Humans Yields 2 Biomarkers, 
Tetrahydrophthalimide (THPI) and Thiazolidine-2-Thione-4-Carboxylic Acid (TTCA) in Urine. 
Drug Chem. Toxicol. 16: 207-225. 
 
Kromhout H, Vermeulen R. 2001. Temporal, personal and spatial variability in dermal exposure. 
Ann. Occup. Hyg. 45: 257-273. 
 
Lappin GJ, Havell LM. Captan:Biotransformation study in the rat. ICI Central Toxicology 
Laboratory: Macclesfield. Unpublished report. 
 
Lavy TL, Mattice JD, Massey JH, Skulman BW. 1993. Measurements of year-long exposure to 
tree nursery workers using multiple pesticides. Arch. Environ. Contam. Toxicol. 24: 123-144. 
 
Lim DS, Shin BS, Yoo SD, Kim HS, Kwack SJ, Alm MY, Lee BM. 2007. Toxicokinetics of 
phthalic acid: The common final metabolite of phthalic acid esters in rats. J. Toxicol. Environ. 
Health-Part A 70: 1344-1349. DOI 10.1080/15287390701432293. 
 
Lotte C, Wester RC, Rougier A, Maibach HI. 1993. Racial differences in the in vivo percutaneous 
absorption of some organic compounds: a comparison between black, Caucasian and Asian 
subjects. Arch. Dermatol. Res. 284: 456-459. 
 
Mangelsdorf S, Otberg N, Maibach HI, Sinkgraven R, Sterry W, Lademann J. 2006. Ethnic 
variation in vellus hair follicle size and distribution. Skin Pharmacol. Physiol. 19: 159-167. DOI: 
10.1159/000093050. 
 
18 
 
Mcjilton CE, Berckman GE, Deer HM. 1983. Captan Exposure in Apple Orchards. Am. Ind. Hyg. 
Assoc. J. 44: 209-210. 
 
Ngo MA, O'Malley M, Maibach HI. 2010. Percutaneous absorption and exposure assessment of 
pesticides. J. Appl. Toxicol. 30: 91-114. DOI: 10.1002/jat.1505. 
 
Poet TS, McDougal JN. 2002. Skin absorption and human risk assessment. Chem. Biol. Interact. 
140: 19-34. 
 
Ritcey G, Frank R, McEwen FL, Braun HE. 1987. Captan residues on strawberries and estimates 
of exposure to pickers. Bull. Environ. Contam. Toxicol. 38: 840-846. 
 
Shah PV, Fisher HL, Sumler MR, Monroe RJ, Chernoff N. 1987. Comparison of the Penetration 
of 14 Pesticides Through the Skin of Young and Adult-Rats. J. Toxicol. Environ. Health 21: 353-
366. 
 
Silva MJ, Samandar E, Preau JL Jr., Reidy JA, Needham LL, Calafat AM. 2007. Quantification of 
22 phthalate metabolites in human urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 860: 
106-112. DOI: 10.1016/j.jchromb.2007.10.023. 
 
Tielemans E, Louwerse E, de Cock J, Brouwer D, Zielhuis G, Heederik D. 1999. Exposure to 
fungicides in fruit growing: Re-entry time as a predictor for dermal exposure. Am. Ind. Hyg. Assoc. 
J. 60: 789-793. 
 
Trivedi S. Captan: Excretion mid tissue retension of a songle pral dose (10 mg/kg) in the rat. ICI 
Central Toxicology Laboratory: Macclesfield. Unpublished report No CTL/P/2820. 
 
Tsai JC, Sheu HM, Hung PL, Cheng CL. 2001. Effect of barrier disruption by acetone treatment 
on the permeability of compounds with various lipophilicities: Implications for the permeability of 
compromised skin. J. Pharm. Sci. 90: 1242-1254. 
 
United States Environmental Protection Agency (US EPA). Initial scientific and mini-economic 
review of captan. Office of Pesticide Programs, Criteria and Evaluation Division: Washington. 
Report No -EPA/540-1-75-012. 
 
van Welie RT, van Duyn P, Lamme EK, Jager P, van Baar BL, Vermeulen NP. 1991. 
Determination of tetrahydrophtalimide and 2-thiothiazolidine-4-carboxylic acid, urinary 
metabolites of the fungicide captan, in rats and humans. Int. Arch. Occup. Environ. Health 63: 181-
186. 
 
Verberk MM, Brouwer DH, Brouwer EJ, Bruyzeel DP, Emmen HH, van Hemmen JJ, Hooisma J, 
Jonkman EJ, Ruijten MW, Salle HJ. 1990. Health effects of pesticides in the flower-bulb culture 
in Holland. Med. Lav. 81: 530-541. 
 
Vermeulen R, Kromhout H, Bruynzeel DP, de Boer EM, Brunekreef B. 2001. Dermal exposure, 
handwashing, and hand dermatitis in the rubber manufacturing industry. Epidemiology 12: 350-
354. 
19 
 
 
Vermeulen R, Stewart P, Kromhout H. 2002. Dermal exposure assessment in occupational 
epidemiologic research. Scand. J. Work Environ. Health 28: 371-385. 
 
Wester RC, Maibach HI. 1983. Cutaneous pharmacokinetics: 10 steps to percutaneous absorption. 
Drug Metab. Rev. 14: 169-205. DOI: 10.3109/03602538308991388. 
 
Williams DT, Blanchfield BJ. 1974. Retention, excretion and metabolism of phthalic acid 
administrated orally to the rat. Bull. Environ. Contam. Toxicol. 12: 109-112. 
 
Winterlin WL, Kilgore W W, Mourer C R, Schoen S R. 1984. Worker Reentry Studies for Captan 
Applied to Strawberries in California. J. Agric. Food Chem. 32 664-672. 
 
Winterlin WL, Kilgore WW, Mourer CR, Hall G, Hodapp D. 1986. Worker Reentry Into Captan-
Treated Grape Fields in California. Arch. Environ. Contam. Toxicol. 15: 301-311. 
 
Wolfe NL, Zepp RG, Doster JC, Hollis RC. 1976. Captan Hydrolysis. J. Agric. Food Chem. 24: 
1041-1045. 
 
Woollen BH. 1993. Biological monitoring for pesticide absorption. Ann. Occup. Hyg. 37: 525-540. 
 
Zainal H, Que Hee SS. 2003. Folpet permeation through nitrile gloves. Appl. Occup. Environ. Hyg. 
18: 658-668. 
 
Zweig G, Leffingwell JT, Popendorf W. 1985. The relationship between dermal pesticide exposure 
by fruit harvesters and dislodgeable foliar residues. J. Environ. Sci. Health B 20: 27-59. 
 
 
20 
 
Table 1. First-order elimination half-lives of THPI and PI in plasma and of THPI, PI and 
phthalic acid in urine following application of 10 mg kg-1 of captan or folpet on the forearm of 
volunteers. 
 
 
Metabolites Matrices 
Mean first-order 
elimination half-life 
(h)a 
(n = 5) 
Coefficient of 
determination 
(R2) 
THPI Plasma 24.7 0.99 
 Urine 18.7 0.86 
PI Plasma 29.7 0.93 
 Urine 28.8 0.90 
Phthalic acid Urine 29.6 0.86 
 
a The apparent elimination half-life (t1/2) was calculated using the equation t1/2 = 0.693 k-1, where 
k is the elimination rate constant obtained from the slope of the linear terminal phase of the plasma 
profile (24-72 h) or urine excretion rate time course (36-96 h) for each metabolite. 
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Table 2. Toxicokinetic parameters for THPI and PI in plasma of volunteers following a 
dermal application of 10 mg kg-1 of captan or folpet on 80 cm2 of the forearm. 
 
 
 First order toxicokinetic values 
 THPI Phthalimide 
Model parametersa Mean SD Mean SD 
 (n=5) (n=4) 
AUC [(nmol x h l-1) kg-1] 137.3 43.38 26.01 14.36 
AUMC [(nmol x h2 l-1) kg-1] 4 772 1 929 532.2 152.5 
MRT (h) 34.07 5.52 22.50 5.54 
CL (l h-1) 0.24 0.07 0.13 0.06 
Vd (l) 7.44 2.14 6.07 2.57 
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Captions to figures 
 
 
Figure 1. Time courses of THPI and PI in plasma of volunteers (expressed as nmol) over a 
72-h period following a single application of 10 mg kg-1 of captan or folpet on 80 cm2 of the 
forearm. Each point represents mean and vertical bars are standard deviations. 
 
Figure 2. Time courses of THPI, PI and phthalic acid excretion rate in urine (expressed as 
nmol/h) of volunteers over a 96-h period following a single application of 10 mg kg-1 of captan or 
folpet on 80 cm2 of the forearm. Each point represents mean and vertical bars are standard 
deviations. 
 
Figure 3. Time courses of THPI, PI and phthalic acid cumulative excretion in urine 
(expressed as nmol) of volunteers over a 96-h period following a single application of 10 mg kg-1 
of captan or folpet on 80 cm2 of the forearm. Each point represents mean and vertical bars are 
standard deviations. 
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